Category: CULTIVATION & RETAIL

WeedMD and Phivida to Enter into Joint Venture for Cannabis-Infused Beverages

SHARE THIS POST CanBev Inc. is positioned to become the premiere cannabis-infused bottling plant in Canada TORONTO and VANCOUVER, March 8, 2018 /CNW/ – WeedMD Inc. (TSX-V:WMD) (OTC:WDDMF) (FSE:4WE) (“WeedMD”), a federally licensed producer and distributor of medical cannabis and Phivida Holdings Inc. (CSE:VIDA; OTC:PHVAF) (“Phivida”), a premium brand of cannabidiol (“CBD”) infused functional beverages and clinical health products, are pleased to announce the signing of a letter of intent (“LOI”) to form a joint venture focused on cannabis-infused beverages. The new joint venture company, Cannabis Beverages Inc. (“CanBev”), plans to develop a production facility at WeedMD’s state-of-the-art greenhouse in Strathroy, Ontario. Click here for a presentation on the Cannabis Beverages Inc. (CanBev Inc.) joint venture project. CanBev will operate one of the first cannabis-infused beverage production facilities in Canada. The joint venture partnership will focus on manufacturing, marketing and distribution of cannabinoid-infused beverages for the medical and future adult-use cannabis markets.WeedMD will be the exclusive cannabis supplier and distributor for CanBev cannabis-infused beverages and will designate production space at its 610,000 sq. ft. state-of-the-art facility in Strathroy for CanBev’s operation. As an emerging cGMP certified food grade production plant, WeedMD’s Strathroy facility will equip CanBev with extensive production infrastructure, including 25,000 sq. ft. of packaging area and cold storage, as well as adequate space to expand for future growth. “As WeedMD builds out its production footprint, we will...

Read More

ICC Labs Provides Operational Update on Recreational Cannabis Business

SHARE THIS POST The Company has reached aggregate production of 1,000 kilograms of dried recreational cannabis. In January 2018, the Government of Uruguay increased the domestic sale price for recreational cannabis by 6.5%.New levels of THC (tetrahydrocannabinol) and CBD (cannabidiol) in dried recreational cannabis are now permitted for sale, THC ≤ 9% and CBD ≥ 3%, specifically. VANCOUVER, British Columbia, March 07, 2018 (GLOBE NEWSWIRE) — ICC Labs Inc. (“ICC Labs” or the “Company”) (TSX-V:ICC) is pleased to provide an operational update with respect to its recreational cannabis business in Uruguay. ICC Labs continues to work with Ministry of Health, IRCCA (Cannabis Regulation and Control Institute) and other partners to improve its production capacity in order to meet Uruguay’s growing domestic demand for recreational cannabis.Recreational Cannabis Production Update Since July 19, 2017, ICC Labs has sold 66,512 packages of recreational cannabis consisting of five grams per package through licensed pharmacies approved by the Ministry of Health and IRCCA. To date, the Company has produced more than 1,000 kilograms of recreational cannabis for the Uruguayan domestic market. Continued increases in Uruguayan Registered Users The Uruguayan recreational cannabis registry registered 17,377 new users from July 19, 2017 to March 4th, 2018, bringing total active registered users to 21,877. The Company also expects authorizations for additional points of sale at new pharmacies seeking sales licenses, which should be supportive to the registered...

Read More

Hiku Brands Applies for Cannabis Oil License, Launches Innovative Extraction Program in Partnership with Vitalis and Secures Prairies Expansion Rights for Tokyo Smoke Brand

SHARE THIS POST FOR IMMEDIATE RELEASE – March 7, 2018 (Toronto): Hiku Brands Company Ltd. (“Hiku” or the “Company”) (CSE:HIKU), Canada’s first vertically-integrated cannabis brand house, is pleased to provide an update of the Company’s recent corporate development initiatives. DOJA Applies for Cannabis Oil License and Signs Innovative Extraction Partnership Agreement with VitalisHiku’s wholly-owned subsidiary DOJA Cannabis Ltd. (“DOJA”), a licensed cannabis producer under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”), submitted its application to Health Canada for the production of medical cannabis oils at its second site facility (the “FUTURE LAB”) located in Kelowna, British Columbia. Hiku is also pleased to announce it has signed a strategic partnership agreement with Vitalis Extraction Technology Inc. (“Vitalis”), whereby Vitalis will advise on the build-out of DOJA’s extraction lab, partner on certain research and development initiatives, and supply the FUTURE LAB with Vitalis’ Q-90 supercritical CO2 extraction system – which is capable of processing up to 80 kg of cannabis flower per day into ultra-pure, exceptionally-clean, high-quality cannabis oils without the use of any toxic solvents. Vitalis is known as the leading manufacturer of high flow rate industrial supercritical CO2 extraction systems that are redefining the capabilities of traditional extraction methodologies. “This is an important step for Hiku, the future of cannabis will be convenience and consistency, and the proliferation of dose-controlled consumption methods will be driven by...

Read More

Significant price reduction for Hydropothecary’s popular Elixir THC spray

SHARE THIS POST New $69-bottle price to make Elixir THC affordable for more Canadians GATINEAU, Quebec, March 06, 2018 (GLOBE NEWSWIRE) — The Hydropothecary Corporation (“Hydropothecary”) (TSX VENTURE:THCX) is pleased to announce a significant price reduction for one of its most popular and innovative products, Elixir THC. Clients can now purchase the country’s first sublingual peppermint oil cannabis mist for $69/15ml bottle. Award-winning Elixir THC contains cannabis oil in a refreshing peppermint oil base that can be used under the tongue or mixed into food or drink. Hydropothecary credits improvements in its cannabis oil extraction processes for its decision to decrease the price of its Elixir THC spray from the original $89/15ml bottle, to the new $69/15ml bottle, a 22% reduction. “Hydropothecary is dedicated to creating and producing the highest-quality innovative products that meet the daily needs of our customers, and are accessible to as many Canadians as possible,” said James McMillan, Hydropothecary’s Vice-President, Business Development. “I am very pleased to be able to pass these lower production costs for our oils and extractions on to our clients.”Along with its refreshing base, Elixir THC contains close to the maximum allowable THC level of 30mg/ml for a cannabis oil under current Health Canada’s Access to Cannabis for Medical Purposes Regulations. Packaged in a discrete, child-resistant spray bottle, Elixir THC provides an enjoyable experience for our customers while protecting the safety...

Read More

Organigram reports Health Canada approval of new grow rooms, increased yields and upward revision to production capacity forecasts

SHARE THIS POST MONCTON, NB, March 6, 2018 /CNW/ – Organigram Holdings Inc. (TSX VENTURE: OGI) (OTCQB: OGRMF) (the “Company” or “Organigram”), a leading licensed producer of medical marijuana based in Moncton, New Brunswick, is pleased to announce that it has received Health Canada approval for the remaining 13 rooms of its 23 room Phase 2 expansion a week ahead of schedule. The Company previously announced the available use of the first 10 rooms of the Phase 2 expansion on February 12, 2018. The Company expects harvests from the Phase 2 expansion to begin the third week of April. Increased Efficiency and Improved Yields The Phase 2 expansion includes significant improvements and efficiencies to the Company’s cultivation and processing systems. Enhancements including a fully automated irrigation system in the Phase 2 grow rooms, automated potting, fully automated waste destruction system and automated packaging lines mean immediate and ongoing cost savings as well as increased yields.Organigram’s standardized, data-based approach to production has been trending yields that are in some cases 50% higher than its previous estimates and the Company fully anticipates this to continue to increase with enhanced improvements in cultivation and environmental design in Phase 3 and Phase 4 as well as through achievements of economies of scale through optimization of its pre-vegetation and cloning processes. “We are seeing some harvest yields that are more than 400 grams per...

Read More

MedReleaf adds the iconic Woodstock brand to its recreational market portfolio

SHARE THIS POST MARKHAM, ON, March 6, 2018 /CNW/ – MedReleaf Corp. (TSX:LEAF), Canada’s first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced it has entered into an exclusive licencing agreement with Woodstock Cannabis Company for use of the iconic Woodstock brand in the Canadian cannabis market. Under the terms of the agreement, MedReleaf will grow and sell a variety of strains and formats under the Woodstock banner, expanding the offering of products as regulations allow. “As a trusted symbol of the values and lifestyles of the Cannabis Community, the authenticity of Woodstock resonates with a wide segment of the population like no other brand,” says Michael Lang, a principal of Woodstock Cannabis Company and one of the producers of the original Woodstock Festival. “We chose to partner with MedReleaf because we are so impressed with their in-depth understanding of the Canadian consumer, with their unparalleled track record of producing award-winning cannabis and with their commitment to innovation. Together we are going to deliver an incredible consumer experience.” In August 1969, the Woodstock Music & Art Fair took place on a dairy farm in Bethel, NY. Over half a million people came to a 600-acre farm to hear 32 leading and emerging performers of the time play over the course of four days (August 15-18). Jimi Hendrix, the Grateful Dead, the Who, Santana, Janis Joplin, The...

Read More